Case report on intravenous octreotide for the treatment of intraoperative vasoplegia following thymoma resection

Wendell H Williams 3rd, Rosheem C Browne, Thao P Bui, A Alex Holmes, Dilip Thakar, Wendell H Williams 3rd, Rosheem C Browne, Thao P Bui, A Alex Holmes, Dilip Thakar

Abstract

Octreotide is a somatostatin analog known for its role in the treatment of acute variceal bleeding, enterocutaneous fistula and carcinoid syndrome. The reduction of portal pressure from splanchnic vasoconstriction has been attributed to the inhibition of nitric oxide synthesis, guanylate cyclase and release of glucagon. Octreotide has many therapeutic applications as a result of the ubiquitous nature of somatostatin receptors throughout the body. The effects of octreotide on vascular tone make it potentially useful in the treatment of intraoperative vasoplegia, hypotension with low systemic vascular resistance with preserved cardiac output that is refractory to adrenergic agonists. We present a case in which a patient undergoing thymoma resection developed vasoplegia that was effectively treated with octreotide. We believe that this case illustrates the need for further investigation on the potential efficacy of octreotide as an adjunct for the treatment of vasoplegia and other forms of shock.

Keywords: Octreotide; non-adrenergic vasopressors; refractory hypotension; shock; thymoma; vasoplegia.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
A copy of the electronic intraoperative record for focused on the period of thymoma resection and refractory hypotension.

References

    1. Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg 2010; 22(2): 140–144.
    1. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med 2009; 60: 355–366.
    1. Reichlin S. Somatostatin. N Engl J Med 1983; 309(24): 1495–1501.
    1. Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003; 18(4): 375–386.
    1. Lamberts SW, van der Lely AJ, de Herder WW, et al. Octreotide. N Engl J Med 1996; 334(4): 246–254.
    1. Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res 2012; 5(5): 161–168.
    1. Chatila R, Ferayorni L, Gupta T, et al. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000; 31(3): 572–576.
    1. Sàbat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998; 43(10): 2184–2189.
    1. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100(4): 879–885.
    1. Sakamoto H. Cardiovascular effects of octreotide, a long-acting somatostatin analog. Card Drug Rev 1999; 17(4): 358–373.
    1. Chan MM, Chan MM, Mengshol JA, et al. Octreotide: a drug often used in the critical care setting but not well understood. Chest 2013; 144(6): 1937–1945.
    1. Saad AF, Maybauer MO. The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock. J Crit Care 2017; 40: 41–45.
    1. Burroughs AK, Planas R, Svoboda P. Optimizing emergency care of upper gastrointestinal bleeding in cirrhotic patients. Scand J Gastroenterol Suppl 1998; 226: 14–24.
    1. Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol 2013; 9(3): 242–249.
    1. Mazzeffi M, Hammer B, Chen E, et al. Methylene blue for postcardiopulmonary bypass vasoplegic syndrome: a cohort study. Ann Card Anaesth 2017; 20(2): 178–181.
    1. Pasin L, Umbrello M, Greco T, et al. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Crit Care Resusc 2013; 15(1): 42–48.
    1. Buzato MA, Viaro F, Piccinato CE, et al. The use of methylene blue in the treatment of anaphylactic shock induced by compound 48/80: experimental studies in rabbits. Shock 2005; 23(6): 582–587.
    1. Hosseinian L, Weiner M, Levin MA, et al. Methylene blue: magic bullet for vasoplegia? Anesth Analg 2016; 122(1): 194–201.
    1. Privistirescu AI, Sima A, Duicu OM, et al. Methylene blue alleviates endothelial dysfunction and reduces oxidative stress in aortas from diabetic rats. Can J Physiol Pharmacol 2018; 96(10): 1012–1016.
    1. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010; 22(4): 275–280.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren